Tuberculosis treatment in complex emergencies: Are risks outweighing benefits?

Tropical Medicine and International Health

Volumn 8, Issue 3, 2003, Pages 211-218

  Biot, Marc ^b   Chandramohan, Daniel ^a   Porter, John D H ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b London Sch of Hyg/Trop Medicine ^*  (Belgium)

Author keywords

Complex emergencies; Compliance rate; Drug resistance; Early treatment result; Economic analysis; Modelling; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

DISEASE TREATMENT; HUMANITARIAN AID; PUBLIC HEALTH; TUBERCULOSIS;

ARTICLE; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; SOCIOECONOMICS; SPUTUM ANALYSIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; EMERGENCIES; HEALTH CARE COSTS; HUMANS; MODELS, THEORETICAL; PATIENT COMPLIANCE; PROGRAM EVALUATION; PUBLIC HEALTH; RELIEF WORK; RISK ASSESSMENT; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY; WAR;

EID: 0242668867     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2003.01025.x     Document Type: Article

References (38)

1. Agutu W (1997) Short-Course Tuberculosis Chemotherapy in rural Somalia. East African Medical Journal 74, 348-352.
2. Baba H, Shinkai A & Izuchi R (1984) Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Bulletin of the International Union against Tuberculosis 59, 26-29.
3. Barr R & Menzies R (1994) The effect of war on tuberculosis. Tubercle and Lung Disease 75, 251-259.
4. Borgdorff MW, Floyd K & Broekmans JF (2002) Interventions to reduce tuberculosis mortality and transmission in low and middle-income countries. Bulletin of the World Health Organization 80, 217-227.
5. Buchanan Smith M & Maxwell S (1994) Linking relief to development: an introduction and overview. IDS Bulletin 25, 4.
6. Burkle FM (1999) Lessons learnt and future expectations of complex emergencies. British Medical Journal 319, 422-426.
7. Centers for Disease Control and Prevention (2002) Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. Morbity and Mortality Weekly Reports 51, 214-215.
8. DeCock K (1994) Impact of interaction with HIV. In: Tuberculosis back to the future (eds J Porter & K McAdam), John Wiley & Sons, Chichester, pp. 35-49.
9. Dejonghe E, Murray CJL, Chum H, Nyangulu D, Salomao A & Styblo K (1994) Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania. International Journal of Health Planning & Management 9, 151-181.
10. Dutt A, Moers D & Stead W (1989) Smear and culture-negative pulmonary Tuberculosis: 4-month short course chemotherapy. American Reviews of Respiratory Disease 139, 867-870.
11. East African/BMRC study (1981) Controlled Clinical Trial of five Short Course (4 month) Chemotherapy regimens in Pulmonary Tuberculosis. American Reviews of Respiratory Disease 123, 165-170.
12. Enarson D & Rouillon A (1994) The epidemiological basis of tuberculosis control. In: Clinical Tuberculosis (ed P Davies), Chapman & Hall, London; pp. 19-30.
13. Grzybowski S & Enarson D (1978) The fate of cases of pulmonary tuberculosis under various treatment Programmes. Bulletin of International Union against Tuberculosis and Lung Disease 53, 70-75.
14. Hong Kong Chest service/BMRC (1982) Controlled trial of four 3-times-weekly regimens and a daily regimen all given for 6-months for pulmonary tuberculosis, second report: the results up to 24 months. Tubercle 63, 89-98.
15. Hong Kong Chest service/TB research centre, Madras/BMRC (1984) A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative-pulmonary tuberculosis. American Reviews of Respiratory Disease 130, 23-28.
16. Hong Kong Chest service/BMRC (1987) Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. American Reviews of Respiratory Disease 136, 1339-1342.
17. Hong Kong Chest service/TB research centre, Madras/BMRC (1989) A Controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum smear negative-pulmonary tuberculosis. American Reviews of Respiratory Disease 139, 871-876.
18. Lutfey M, Della-Latta P, Kapur V et al. (1996). Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. American Journal of Respiratory and Critical Care Medicine 153, 837-840.
19. Macrae J & Zwi A (1994) Famine, complex emergencies and international policy in Africa: an overview. In: War and Hunger: Rethinking international responses to complex emergencies (eds JMacrae, A Zwi, M Duffield & H Slim), Zed Books, London, pp. 6-36.
20. March F, Garria X, Rodriguez P et al. (1997) Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clinical Infectious Diseases 25, 1044-1047.
21. Murray C, Styblo K & Rouillon A (1990) Tuberculosis in developing countries: burden, intervention and cost. Bulletin of International Union against Tuberculosis and Lung Disease 65, 6-23.
22. Murray C, Styblo K & Rouillon A (1993) Tuberculosis. In: Diseases Control Priorities in Developing Countries (eds D Jamison, W Mosley, A Measham & JL Bobadilla), Oxford Medical Publications, Oxford, pp. 233-259.
23. Perlman DC & Salomon N (1996) Selective malabsorption and the origin of mono-rifampin resistant Mycobacterium tuberculosis. (Correspondence). American Journal of Respiratory and Critical Care Medicine 154, 1213.
24. Perriëns J, St. Louis M, Mukadi et al. YB (1995) Pulmonary tuberculosis in HIV infected patients in Zaire. New England Journal of Medicine 332, 779-784.
25. Shimao T (1986) Review of tuberculosis control programmes in the Far East Region of the IUATLD. Bulletin of the International Union against Tuberculosis and Lung Disease 64, 7-20.
26. Schulzer M, Fitzgerald J, Enarson D & Grzybowski S (1992) An estimate of the future size of the tuberculosis problem in sub-Saharan Africa resulting from HW infection. Tubercle and Lung Disease 73, 52-58.
27. Singapore Tuberculosis Service/BMRC (1981) Clinical trial of 6-month and 4-month regimens of chemo-therapy in the treatment of pulmonary tuberculosis the results up to 30 months. Tubercle 62, 95-102.
28. Singapore Tuberculosis Service/BMRC (1986) Long-term Follow-up of a Clinical Trial of 6-month and 4-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. American Reviews of Respiratory Disease 133, 779-783.
29. Singapore Tuberculosis Service/BMRC (1988) Five-year follow-up of a Clinical Trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. American Reviews of Respiratory Disease 137, 147-1150.
30. Sonnenberg P, Murray J, Glynn J, Shearer S, Kambashi B & Godfrey-Faussett P (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358, 1687-1693.
31. TB Research Centre Madras and National TB Institute, Bangalore, (1986) A controlled trial of 3- and 5-month regimens in the treatment of sputum-smear-positive pulmonary tuberculosis. American Reviews of Respiratory Disease 134, 27-33.
32. TB Research Centre Madras and National TB Institute, Bangalore, (1990) 5-year result of a 3- and 5-month regimen for the treatment of sputum-positive pulmonary tuberculosis. Tubercle 71, 253-258.
33. Van Ham T (1998) Report on interviews with agencies responsible for TB programs in Southern Sudan. 11/97-02/98. New Sudan Council of Churches.
34. Van Herp M (1998) Somalia. Evaluation of the TB programme in Kismayu (MSF Belgium).
35. Tuberculosis Research Centre, Madras, (1983) Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary TB in South India. Tubercle 64, 73-91.
36. Vynnycky E & Fine PE (1998) The long-term dynamics of tuberculosis and other diseases with long serial: intervals implications of and for changing reproduction numbers. Epidemiology and Infection 121, 309-324.
37. WHO (1997) The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis Drug Resistance in the World (WHO/TB/97.229) WHO, Geneva.
38. WHO, UNHCR (1997) Tuberculosis Control in Refugee Situations: An Inter-agency Field Manual (Global Tuberculosis Programme) (WHO/TB/97.221), WHO, Geneva.